Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 2 de 2
1.
Macromol Biosci ; 22(6): e2100474, 2022 06.
Article En | MEDLINE | ID: mdl-35089646

The development of hydrogel-integrated soft materials via the incorporation of therapeutic medicines into biocompatible hydrogels, serving as host, will significantly contribute to advances in medical diagnosis and treatment. Furthermore, intelligent hydrogels having the ability to respond to local environmental conditions offer a promising approach for the development of novel solutions in the biomedical field. Bioinspired intelligent hydrogels are now becoming a potentially powerful biomaterial class for tissue engineering, drug delivery, and medical device. Recent advances include bioinspired intelligent hydrogels that possess unique mechanical and optical properties as a result of their nature-inspired complex-structured design. This review highlights the latest advances in intelligent bionic hydrogels, as well as strategies targeting smart response of their characteristics across multiple dimensions (such as temperature, light, pH, among others). Finally, the potential development and prospective application of mimicking the natural intelligence of multifunctional medical hydrogels are also discussed.


Biocompatible Materials , Hydrogels , Biocompatible Materials/chemistry , Biocompatible Materials/therapeutic use , Drug Delivery Systems , Hydrogels/chemistry , Hydrogels/therapeutic use , Temperature , Tissue Engineering/methods
2.
Front Mol Biosci ; 8: 722864, 2021.
Article En | MEDLINE | ID: mdl-34901150

Background: Transcatheter arterial embolization (TAE) is regarded as an effective treatment for patients with symptomatic hepatic hemangioma. However, few studies have evaluated the efficacy of TAE alone for treating hepatic hemangioma. The aim of this study was to identify the factors that influence the response to TAE and formulate a quantitative nomogram to optimize the individualized management of hepatic hemangioma. Methods: We retrospectively studied 276 patients treated with TAE for hepatic hemangioma at our center from January 2011 to December 2019. The full cohort was randomly divided into training and validation cohorts. After assessing the potential predictive factors for the efficacy of TAE in the training cohort, a nomogram model was established and evaluated by discrimination and calibration. Results: During follow-up, the symptom relief rate was 100%. The tumor blood supply (p < 0.001), tumor number (p = 0.004), and tumor size (p = 0.006) were identified as significant predictors of the failure of tumor shrinkage in response to TAE. The nomogram model showed favorable discrimination and calibration, with a C-index of 0.775 (95% CI, 0.705-0.845) in the training cohort, which was further confirmed in the validation cohort (C-index 0.768; 95% CI, 0.680-0.856). The side effects of TAE were relatively minor and included mainly abdominal pain, nausea, vomiting, fever, and the presence of elevated hepatic transaminases. Conclusion: TAE is a safe and effective treatment for symptomatic hepatic hemangioma. The established nomogram performed well for the estimation of the effect of TAE in patients with hepatic hemangioma and can facilitate the selection of patients who would benefit most from the treatment.

...